drugset / Trial / NCT06688123

Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects

NCT06688123

Phase 2 Completed 275 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of SHR-3167 compared with insulin glargine after treatment in insulin naïve subjects with type 2 diabetes treated with metformin alone or in combination with SGLT2 subjects.

Timeline

Start
2025-01-08
Primary completion
2026-04-22
Completion
2026-04-22

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-3167 Unknown
Comparator insulin glargine Protein / enzyme biologic